{
    "nctId": "NCT05958199",
    "briefTitle": "A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7",
    "officialTitle": "A Phase 1a/1b, Dose-Escalation/Dose-Expansion Study of NPX267 in Subjects With Solid Tumors Known to Express HHLA2/B7-H7",
    "overallStatus": "RECRUITING",
    "conditions": "Metastatic Malignant Neoplasm",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 131,
    "primaryOutcomeMeasure": "Incidence of dose limiting toxicity",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed recurrent, metastatic solid tumor refractory to standard of care therapy in one of the following indications: Part 1a: non-small cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), colorectal carcinoma (CRC), cholangiocarcinoma (CCA), pancreatic cancer (PDAC), urothelial carcinoma (UCC), gastric/gastroesophageal carcinoma, triple negative breast carcinoma, endometrial carcinoma, cervical cancer, osteosarcoma, and prostate cancer\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Normal bone marrow, kidney and liver function\n* Willing to use highly effective contraceptive measures throughout the trial\n\nExclusion Criteria:\n\n* Have any unresolved toxicity of Grade \u2265 2 from previous anti-cancer treatment, except for alopecia, chronic neuropathy \\> 6 months, or changes in skin pigmentation\n* Have known or suspected brain metastases, unless they are clinically stable\n* Known autoimmune disease requiring immunosuppressive treatment requiring the equivalent of more than 10 mg prednisone daily\n* History of grade 3 immune-related pneumonitis or colitis",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}